Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PUR-WASH vs AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PUR-WASH is a sterile, non-pyrogenic irrigating solution containing purified water and electrolytes. Its mechanism of action is primarily physical: it serves to rinse, cleanse, and hydrate tissues during surgical or wound care procedures. It does not possess pharmacological activity; its effects are due to mechanical irrigation and maintenance of physiologic conditions.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.
Sterile irrigation of body cavities, wounds, and surgical sites,Cleansing of wounds and burns,Rinsing of instruments and equipment,Hydration of tissues during surgical procedures
Hypertension,Edema associated with congestive heart failure, cirrhosis, or nephrotic syndrome,Hypokalemia prevention or correction in patients on diuretics
Not applicable; PUR-WASH is a sterile irrigating solution for topical use only, not for systemic administration. No standard systemic dose.
One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.
Terminal elimination half-life is 12-18 hours (mean 15 h). In patients with moderate renal impairment (Cr Cl 30-50 m L/min), half-life may extend to 24-30 hours; severe impairment (Cr Cl <30 m L/min) may prolong to >40 hours, requiring dose adjustment.
Amiloride: 6-9 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment, heart failure).
PUR-WASH is not metabolized; it is absorbed and excreted unchanged by the kidneys if administered intravenously or absorbed from wounds. When used topically or for irrigation, minimal systemic absorption occurs.
Amiloride is not metabolized; excreted unchanged in urine. Hydrochlorothiazide is not extensively metabolized; small amounts are metabolized hepatically via CYP450 enzymes, but the exact pathways are not well defined.
Primarily renal excretion of unchanged drug (85-90%), with 10-15% fecal elimination via biliary secretion.
Amiloride: 50% unchanged in urine, 40% in feces (biliary); Hydrochlorothiazide: >95% unchanged in urine.
Approximately 98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein (AAG).
Amiloride: ~23%; Hydrochlorothiazide: 40-68% (primarily to albumin).
Vd = 0.3-0.5 L/kg, indicating moderate distribution into total body water; higher Vd observed in obesity (0.6 L/kg) due to lipophilicity.
Amiloride: 350-440 L (5-6 L/kg in 70 kg adult), indicating extensive tissue distribution; Hydrochlorothiazide: 3-5 L/kg, distributes into extracellular space.
Oral: 95-100% (first-pass metabolism negligible); Intramuscular: 100%; Subcutaneous: 90-95% (site-dependent).
Amiloride: 50-80% (oral); Hydrochlorothiazide: 60-80% (oral).
No systemic absorption; not applicable.
Contraindicated if GFR <30 m L/min or serum creatinine >2.5 mg/d L. For GFR 30-50 m L/min: use with caution and monitor electrolytes; avoid if further renal impairment.
No systemic absorption; not applicable.
Child-Pugh Class A: no adjustment; Class B: reduce dose or use alternative; Class C: avoid use (risk of hepatic encephalopathy).
No systemic absorption; use as directed for wound irrigation per local protocol.
Not established; safety and efficacy not determined in children.
No systemic absorption; use as directed for wound irrigation per local protocol.
Start at lowest dose, monitor electrolytes and renal function; increased sensitivity to hypotension and electrolyte disturbances; avoid if creatinine clearance <30 m L/min.
None
None
For external use only. Not for injection. Use only if solution is clear and container undamaged. Discard unused portion. Do not use for irrigation of closed cavities without adequate drainage. Monitor fluid and electrolyte balance when large volumes are used, especially in patients with renal impairment or cardiac failure. Prolonged contact with tissues may cause maceration.
Hyperkalemia risk, especially with renal impairment, diabetes, or concomitant use of potassium supplements, ACE inhibitors, or aldosterone antagonists,Electrolyte imbalances (hyponatremia, hypomagnesemia, hypochloremia),Azotemia and renal impairment,Sulfonamide hypersensitivity cross-reactivity (hydrochlorothiazide is a sulfonamide derivative),Acute angle-closure glaucoma (rare with thiazides),Monitor serum electrolytes, renal function, and blood glucose
Hypersensitivity to any component. Do not use for irrigation of body cavities where absorption may lead to fluid overload or electrolyte disturbances without appropriate monitoring. Not for intravascular or intrathecal use.
Anuria,Acute or chronic renal insufficiency (creatinine clearance <10 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Concomitant use of other potassium-sparing diuretics, potassium supplements, or amiloride-containing drugs,Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs
None relevant as PUR-WASH is a topical irrigating solution with no systemic absorption.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) in large amounts. Limit salt intake. Grapefruit juice may increase hydrochlorothiazide absorption; avoid concurrent consumption.
PUR-WASH has not been formally studied in pregnant women. Animal studies are lacking. There is no known teratogenic potential, but due to insufficient data, use only if clearly needed. No specific trimester risks have been identified.
First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence is inconclusive. Second and third trimesters: Hydrochlorothiazide may cause fetal/neonatal electrolyte disturbances, jaundice, and thrombocytopenia. Amiloride has not been associated with major teratogenic effects in animal studies, but human data are inadequate. Overall risk is moderate; avoid in pregnancy if possible, especially for treatment of hypertension, as alternatives exist.
It is unknown whether PUR-WASH is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need.
Hydrochlorothiazide is excreted into breast milk in low amounts (M/P ratio approximately 1.5); amiloride is also excreted in animal milk but human data lacking. Potential for neonatal electrolyte imbalance and thrombocytopenia from thiazide. Use during breastfeeding is not recommended unless essential. Monitor infant for signs of dehydration and electrolyte disturbances.
No pharmacokinetic studies have been performed in pregnant women. Currently, no dose adjustment is recommended for PUR-WASH during pregnancy, but caution is warranted due to limited data.
No specific dose adjustments recommended for pregnancy due to lack of pharmacokinetic studies; however, increased renal clearance during pregnancy may reduce diuretic efficacy. Caution with hypovolemia and electrolyte disturbances. Use lowest effective dose and consider alternative agents for hypertension in pregnancy (e.g., methyldopa, labetalol).
PUR-WASH is a sterile, preservative-free irrigating solution indicated for wound cleansing and debridement. Use at room temperature to avoid thermal injury. Do not use for prolonged irrigation of closed body cavities due to risk of fluid absorption. For external wounds only; not for injection or ophthalmic use.
Amiloride is potassium-sparing; hydrochlorothiazide causes potassium loss. The combination offsets hypokalemia risk. Monitor serum potassium, especially in renal impairment or with NSAIDs. Avoid in anuria or severe renal disease. Onset of diuresis: 2 hours; peak effect: 6-12 hours; duration: 24 hours.
Do not ingest or inject this solution; it is for external wound cleaning only.,Discard any unused portion after opening; do not reuse or store opened bottles.,Do not apply heat or microwave the solution to avoid burns.,Use within 24 hours of opening to maintain sterility.,If irritation or infection occurs, stop use and consult your healthcare provider.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug increases urine output and may cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid potassium supplements or salt substitutes containing potassium unless directed by your doctor.,Limit alcohol intake as it can increase dizziness and orthostatic hypotension.,Notify your doctor if you experience muscle cramps, weakness, irregular heartbeat, or excessive thirst.
No interactions on record
"The coadministration of Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), with Chlorothiazide, a thiazide diuretic, may result in a diminished antihypertensive and diuretic effect of Chlorothiazide. Sulindac can inhibit renal prostaglandin synthesis, leading to sodium and water retention, which counteracts the natriuretic and hypotensive actions of Chlorothiazide. This interaction may result in reduced blood pressure control and potentially exacerbate edema in patients with hypertension or heart failure."
"Concomitant use of torasemide, a loop diuretic, and chlorothiazide, a thiazide diuretic, produces synergistic blockade of sodium reabsorption along the nephron, leading to profound diuresis, electrolyte disturbances, and volume depletion. This combination increases the risk of severe hypokalemia, hyponatremia, hypomagnesemia, and metabolic alkalosis, potentially precipitating cardiac arrhythmias, hypotension, or renal impairment, especially in patients with compromised renal function or those on digoxin or antiarrhythmics."
"Flurandrenolide, a topical corticosteroid, can be absorbed systemically and enhance the hypokalemic effect of chlorothiazide, a thiazide diuretic. This interaction occurs through additive potassium-wasting actions: flurandrenolide promotes renal potassium excretion via mineralocorticoid-like effects, while chlorothiazide increases distal tubular potassium loss. Clinically, this can lead to severe hypokalemia, potentially causing cardiac arrhythmias, muscle weakness, and impaired glucose tolerance."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PUR-WASH vs AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, answered by our medical review team.
PUR-WASH is a Irrigation Solution that works by PUR-WASH is a sterile, non-pyrogenic irrigating solution containing purified water and electrolytes. Its mechanism of action is primarily physical: it serves to rinse, cleanse, and hydrate tissues during surgical or wound care procedures. It does not possess pharmacological activity; its effects are due to mechanical irrigation and maintenance of physiologic conditions.. AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is a Thiazide Diuretic that works by Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PUR-WASH and AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PUR-WASH is: Not applicable; PUR-WASH is a sterile irrigating solution for topical use only, not for systemic administration. No standard systemic dose.. The standard adult dose of AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is: One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PUR-WASH and AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PUR-WASH is classified as Category C. PUR-WASH has not been formally studied in pregnant women. Animal studies are lacking. There is no known teratogenic potential, but due to insufficient data, use only if clearly nee. AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is classified as Category A/B. First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.